SCH: Context-aware Freezing of Gait Mitigation in Real-world Setting
NCT ID: NCT04746846
Last Updated: 2025-08-22
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
12 participants
INTERVENTIONAL
2021-06-11
2025-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
The PDVibe3 is an investigational device, which means it has not been approved by the U.S. Food and Drug Administration (FDA). The UG motion sensor is also an investigational device.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Optimizing Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease
NCT03883217
Vibrotactile Foot Device for Freezing of Gait in Parkinson's Disease
NCT06147713
Overcoming Gait Freeze in Parkinson's Disease Using Responsive Cueing
NCT05019469
Smartshoes for Freezing of Gait in Parkinson's Disease
NCT07001072
Vibrational Therapy to Improve Gait and Balance in Parkinson's Disease
NCT03872115
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Participants will be asked to walk on certain paths, and when the device detects a freeze in their gait, they will receive a dose of vibration to their feet. This vibration is felt differently by different people and it may feel very light or a little stronger (like a phone set to vibrate), or it may feel somewhere in between.
During the study, participants will be asked to do the following things:
1. Visit the research site at VCU, one time for the study
2. Complete a short cognitive exam
3. Answer questions about their medical history
4. Complete a few brief surveys about fatigue, balance, falls, freezing of gait, quality of life, and activities of daily living
5. Complete a 10-meter walk test
6. Wear the UG motion sensor (which detects FoG) on each ankle
7. Wear the PDVibe3 (which provides vibration) on each ankle
8. Walk five, 5-meter scenarios without vibration, and then again three more times with vibration therapy in a public setting on VCU campus. The five scenarios include:
1. Walking through a narrow passage
2. Walk and turn 540 degrees
3. Walk toward a chair
4. Walk while performing a verbal task
5. Walk through a door before it closes
Participants will be able to take breaks at any time if they feel tired. Participants will be photographed and videotaped during the walking sessions, but faces will be blurred so that the recordings will not be identifiable.
Participation in this study can last up to 5 hours with several breaks. Approximately 20 individuals will participate in this study.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vibration therapy
5-meter walk scenarios with vibration therapy
UG motion sensor with PDVibe3
UG motion sensor (which detects FoG) on worn each ankle. PDVibe3 (which provides vibration) on worn each ankle
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
UG motion sensor with PDVibe3
UG motion sensor (which detects FoG) on worn each ankle. PDVibe3 (which provides vibration) on worn each ankle
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Parkinson's disease (PD) diagnosed by a movement disorder specialist using UK Brain Bank criteria,
* are able to walk independently or with a simple device (e.g., cane or walker), and
* are observed by the research team to have PD-related FoG in at least two of the five previously described common trigger scenarios (i.e., freezing upon gait initiation, walking through tight quarters, freezing when changing directions, approaching a visual target, dual tasking, and stressful, time sensitive situations such as entering an elevator before the doors close).
Exclusion
* individuals with known Parkinson plus syndrome,
* presence of dementia (Montreal Cognitive Assessment \< 21),
* an additional disorder (not related to PD) impairing gait,
* history of implantable cardiac device or any other implanted electronic device except DBS,
* peripheral neuropathy (determined by use of tuning fork to check for ability to feel vibration),
* any condition that, in the opinion of the PI, would compromise participant safety, data integrity, or data interpretation,
* pregnancy.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Neurological Disorders and Stroke (NINDS)
NIH
Virginia Commonwealth University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Virginia Commonwealth University
Richmond, Virginia, United States
Countries
Review the countries where the study has at least one active or historical site.
Provided Documents
Download supplemental materials such as informed consent forms, study protocols, or participant manuals.
Document Type: Study Protocol
Document Type: Statistical Analysis Plan
Document Type: Informed Consent Form
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HM20020085
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.